Daxor Corporation (DXR) Stock Score, Valuation & Financial Research
Daxor Corporation is in the Healthcare sector and Medical - Instruments & Supplies industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 52/100.
Quick answer for DXR
Daxor Corporation currently has a Wall Street Score of 52/100. The stored market price is $11.47. Its financial score is 16/100. Its valuation score is 72/100. The latest WSS change is +0.9 points. These figures are a research snapshot, not a buy or sell recommendation.
What Daxor Corporation does
Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms. It is utilized across a wide spectrum of medical and surgical contexts. Prior to May 1973, the organization operated under the name Idant Corporation.
DXR financial snapshot
- Wall Street Score:
- 52/100
- Current price:
- $11.47
- Market capitalization:
- $67.0M
- Revenue:
- $869K
- Net income:
- $8.0M
- Free cash flow:
- $-604K
- Cash:
- $0
- Total debt:
- $112K
- EPS:
- 1.60
- P/E ratio:
- 7.2x
- Financial score:
- 16/100
- Valuation score:
- 72/100
- Revenue score:
- 54/100
What stands out
- Reported year-over-year revenue growth is +0.7%.
- Free cash flow is $-604K, showing cash burn in the current stored period.
- The balance sheet shows $0 of cash versus $112K of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.9 points: DXR increased 0.9 points because Valuation improved by 3.6 points.
What the numbers mean
Its current valuation score is 72/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 16/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-06.
How to research DXR
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.